Pivotal bioVenture Partners Fund I, L.P. Insider Profile
4 Followers
Pivotal bioVenture Partners Fund I, L.P., Ten Percent Owner at Entasis Therapeutics Holdings, holds 1.57M shares in Inozyme Pharma (Ticker: INZY), holds 1.79M shares in AKOUOS (Ticker: AKUS), holds 1.18M shares in Entasis Therapeutics Holdings (Ticker: ETTX). Most recently, Pivotal bioVenture Partners Fund I, L.P. Bought ― shares of Inozyme Pharma on Aug 03, 2023 for an estimated value of 4.00M.
Pivotal bioVenture Partners Fund I, L.P. insider profile FAQ
What is the percentage of profitable transactions made by Pivotal bioVenture Partners Fund I, L.P.?
The percentage of profitable transactions made by Pivotal bioVenture Partners Fund I, L.P. is 25%.
What is the average return per transaction made by Pivotal bioVenture Partners Fund I, L.P.?
The average return per transaction made by Pivotal bioVenture Partners Fund I, L.P. is -14.30%.
What stocks does Pivotal bioVenture Partners Fund I, L.P. hold?
Pivotal bioVenture Partners Fund I, L.P. holds: ETTX, AKUS, INZY stocks.
What was Pivotal bioVenture Partners Fund I, L.P.’s latest transaction?
Pivotal bioVenture Partners Fund I, L.P. latest transaction was an Informative Buy of $4.00M.
What was Pivotal bioVenture Partners Fund I, L.P.'s most profitable transaction?
Pivotal bioVenture Partners Fund I, L.P.’s most profitable transaction was an Informative Buy of INZY stock on April 20, 2022. The return on the trade was 30.30%.
What is Pivotal bioVenture Partners Fund I, L.P.'s role in Entasis Therapeutics Holdings?
Pivotal bioVenture Partners Fund I, L.P.'s role in Entasis Therapeutics Holdings is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.